前不久,有些媒体对众多的白酒企业纷纷涉足生物医药行业,进行了大量报道,有人认为这些企业可能是“分散突围”,更有人认为此举大有“弃酒逃生”之嫌。的确,近年白酒业产销量一直低迷,再加上成本增加,竞争激烈,尤其是国家有关政策,使其发展空间日渐狭窄,而白酒企业之所以选择生物医药,一是因为其日后的高成长性,二则是白酒行业本身就与发酵行业同属一脉,而发酵又与生物有着千丝万缕的关联,于是这种“逃生”便不仅有一定必然性,甚至于还有一定的普遍性。 Not long ago, some media had conducted numerous reports on numerous liquor enterprises that had entered the biomedical industry. Some people thought that these enterprises may be “decentralized breakouts.” Some people even think that this move was suspected of “abandoning alcohol to escape”. Indeed, in recent years, the production and sales volume of the liquor industry has been sluggish, coupled with increased costs and fierce competition. In particular, the relevant policies of the state have made its development space increasingly narrow. The reason why liquor companies choose biopharmaceuticals is because of their high growth potential in the future. Second, the liquor industry itself is in the same vein as the fermentation industry, and fermentation is inextricably linked with biology. Therefore, this “escape” is not only certain but also has some universality.